3dGRO^® Breast Organoids (Donor 6)

Patient derived organoids (PDO) are tissue derived, novel in vitro 3D cell models that recapitulate some key features of the respective organ, thus representing a more in vivo-like alternative to traditional 2D cell cultures. In addition, PDOs offer possible means to reduce animal model use. PDO maybe derived from resections or biopsy of adult tissue and are phenotypically and genetically stable in culture. PDO are an ideal platform for drug screening, disease modeling and tumor immunity studies, and may also be modified by gene editing.

Worldwide, breast cancer (BC) is the most commonly diagnosed cancer among women. In the United States, BC accounts for 1 in 3 of all new female cancer cases each year. BC consists of at least 21 distinct histological subtypes and four major molecular subtypes. The grade and cell proliferation may also be used to classify BC subtypes. Almost 81% BC are invasive, and >75% of such invasive cancers are ductal carcinomas, commonly called invasive ductal carcinoma (IDC). It is important to note that the subtypes show overlaps and there maybe differences in clinical approximations and molecular methods to classify BCThe major molecular subtypes are:

• Luminal A (HR+/HER2-): This subtype expresses hormone receptors (HR) for estrogen, progesterone, or both. This is the most common BC subtype, is less aggressive and responds to hormone therapy.
• Luminal B (HR+/HER2+): This subtype expresses the epidermal growth factor receptor HER2 and may also be highly positive for the cell proliferation marker Ki67. Luminal B subtype usually shows poorer prognosis than Luminal A.
• Triple negative or basal-like (HR-/HER2-): This subtype does not express HR or HER2, and therefore have the poorest outcome since as it is minimally responsive to hormone therapy or HER2-targeted treatment. Triple negative BC is more common in black or premenopausal women and also in patients with BRCA1 mutation.
• HER2-enriched (HR-/HER2+): With recent advances in HER2-targeted therapies (such as cell therapy), this subtype now shows significantly improved prognosis.
  
  Cell Line Characteristics :
  Sex: Female
  Age: 68
  Organ: Breast (Tumor)
  Disease: Infiltrating Ductal Carcinoma (IDC), ER+/PR+/HER2-
  History: High blood pressure (Almodipine/Spironolactone), cholesterol (Pravastatin), asthma (Atrovent/Singulair), migraine (Rizatriptan/Topiramate), nerve pain (Gabapentin/Tramadol), depression (Zoloft).
  3dGRO^® PDO were derived utilizing HUB Organoid Technology. The purchaser of this product shall agree to HUB’s terms of use (listed below), which shall be separately acknowledged and accepted by such purchaser, prior to transfer of this product to purchaser.
  

Cryopreserved patient derived breast tumor organoids (PDOs)

Store in liquid nitrogen. The organoids can be cultured for at least 5 passages after initial thawing without significantly affecting the cell marker expression and functionality.

3dGRO^® is a trademark of Merck KGaA, Darmstadt, Germany.
3dGRO^® organoids were derived utilizing HUB Organoid Technology.
The purchaser of this product shall agree to HUB′s terms of use, which shall be separately acknowledged and accepted by such purchaser, prior to transfer of this product to purchaser.

3dGRO is a registered trademark of Merck KGaA, Darmstadt, Germany

Subject to local law, this product is intended to be sold for internal in vitro research use only subject to terms and conditions found here: www.sigmaaldrich.com/pdouse. This product may not be: re-engineered or copied; used to make derivatives or modifications; used to develop, test, or manufacturer a commercial product; used as a component in a commercial product; resold or licensed; used in any clinical applications or trials; or used in humans. A license or limited commercial use agreement is required for use by any for-profit entity, use in services, and use in sponsored academic research. For information regarding any such use, please contact organoids@milliporesigma.com